Review



csl-112  (CSL Behring)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    CSL Behring csl-112
    Csl 112, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-112/csl112/bio_rxiv__2025__07__09__663869-19-14-8
    Average 90 stars, based on 1 article reviews
    csl-112 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Isolation:

    Article Title: Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis
    Article Snippet: , CSL-112 , CSL Behring Inc , Intravenous , Not yet , Phase 3 , [ ] NCT03473223 .

    Article Title: Lipid-Lowering Agents
    Article Snippet: However, a third infused apo A-I analogue, CSL-112 (CSL Behring), recently entered a large phase 3 ASCVD outcomes trial in which ≈17 400 patients with postacute coronary syndrome will receive either 6 g of CSL112 or placebo, administered once weekly for 4 weeks, with the primary end point being occurrence of a major cardiovascular event within 90 days (AEGIS-II [Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome]; www.clinicaltrials.gov: NCT03473223).

    Article Title: Aerosolized ApoA1 Nanoparticles Synthesized by Microfluidics Cross the Lung Barrier and Modulate Inflammation
    Article Snippet: To reduce the cholesterol burden in atherosclerotic plaques, CSL Behring has developed CSL-111 and CSL-112 formulations, composed of phospholipids and ApoA1 isolated from human plasma.

    Article Title: Recent developments in modulating atherogenic lipoproteins
    Article Snippet: Purpose of review Randomized clinical trials have assessed the effects of several classes of drugs on plasma cholesterol levels in patients with coronary artery disease.. Agents including niacin, fibrates and statins significantly lower LDL-cholesterol, but tolerance issues and undesirable side-effects are common.. Residual risk may also be present in patients with persistently low HDL-cholesterol despite a reduction in LDL-cholesterol.

    Article Title: HDL in sepsis – risk factor and therapeutic approach
    Article Snippet: CSL-111 is a rHDL originally produced by CSL Behring for the intention of treating atherosclerosis, making it through Phase II Clinical Trial before being superseded by CSL-112, CSL Behring’s current investigational rHDL therapeutic ( ).

    Clinical Proteomics:

    Article Title: Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis
    Article Snippet: , CSL-112 , CSL Behring Inc , Intravenous , Not yet , Phase 3 , [ ] NCT03473223 .

    Article Title: Lipid-Lowering Agents
    Article Snippet: However, a third infused apo A-I analogue, CSL-112 (CSL Behring), recently entered a large phase 3 ASCVD outcomes trial in which ≈17 400 patients with postacute coronary syndrome will receive either 6 g of CSL112 or placebo, administered once weekly for 4 weeks, with the primary end point being occurrence of a major cardiovascular event within 90 days (AEGIS-II [Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome]; www.clinicaltrials.gov: NCT03473223).

    Article Title: Aerosolized ApoA1 Nanoparticles Synthesized by Microfluidics Cross the Lung Barrier and Modulate Inflammation
    Article Snippet: To reduce the cholesterol burden in atherosclerotic plaques, CSL Behring has developed CSL-111 and CSL-112 formulations, composed of phospholipids and ApoA1 isolated from human plasma.

    Article Title: Recent developments in modulating atherogenic lipoproteins
    Article Snippet: Purpose of review Randomized clinical trials have assessed the effects of several classes of drugs on plasma cholesterol levels in patients with coronary artery disease.. Agents including niacin, fibrates and statins significantly lower LDL-cholesterol, but tolerance issues and undesirable side-effects are common.. Residual risk may also be present in patients with persistently low HDL-cholesterol despite a reduction in LDL-cholesterol.

    Article Title: HDL in sepsis – risk factor and therapeutic approach
    Article Snippet: CSL-111 is a rHDL originally produced by CSL Behring for the intention of treating atherosclerosis, making it through Phase II Clinical Trial before being superseded by CSL-112, CSL Behring’s current investigational rHDL therapeutic ( ).



    Similar Products

    csl-112  (CSL Behring)
    90
    CSL Behring csl-112
    Csl 112, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-112/csl112/bio_rxiv__2025__07__09__663869-19-14-8
    Average 90 stars, based on 1 article reviews
    csl-112 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    csl-112  (Mimetics)
    90
    Mimetics csl-112
    Csl 112, supplied by Mimetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-112/apo+a+i+mimetics+csl+112/pmc10812436-282-0-20
    Average 90 stars, based on 1 article reviews
    csl-112 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    apoa1 csl-112  (Mimetics)
    90
    Mimetics apoa1 csl-112
    Summary of animal studies targeting HDL in various pathologies.
    Apoa1 Csl 112, supplied by Mimetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-112/apoa1+mimetics/pmc10045384-68-13-1
    Average 90 stars, based on 1 article reviews
    apoa1 csl-112 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    apo a–i mimetics csl-112  (Mimetics)
    90
    Mimetics apo a–i mimetics csl-112
    Summary of animal studies targeting HDL in various pathologies.
    Apo A–I Mimetics Csl 112, supplied by Mimetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-112/apo+a+i+mimetics+csl+112/pmc05355390-28-8-6
    Average 90 stars, based on 1 article reviews
    apo a–i mimetics csl-112 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    csl-112  (Cerenis Therapeutics)
    90
    Cerenis Therapeutics csl-112
    Summary of animal studies targeting HDL in various pathologies.
    Csl 112, supplied by Cerenis Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-112/csl+112/pm26169307-159-2-3
    Average 90 stars, based on 1 article reviews
    csl-112 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    hdl mimetic csl-112  (CSL Behring)
    90
    CSL Behring hdl mimetic csl-112
    Summary of animal studies targeting HDL in various pathologies.
    Hdl Mimetic Csl 112, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/csl-112/csl112/10__1194_slash_jlr__r051367-52-5-12
    Average 90 stars, based on 1 article reviews
    hdl mimetic csl-112 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Summary of animal studies targeting HDL in various pathologies.

    Journal: Biomedicines

    Article Title: HDL-Based Therapy: Vascular Protection at All Stages

    doi: 10.3390/biomedicines11030711

    Figure Lengend Snippet: Summary of animal studies targeting HDL in various pathologies.

    Article Snippet: ApoA1 mimetics (e.g., L-4F and D-4F), recombinant apoA1 protein CER-001, a formulation of apoA1 CSL-112 obtained from plasma, and autologous administration of apoA1 obtained from the patient all showed good tolerability results in the first phase of clinical trials for ACS or stable coronary heart disease [ ].

    Techniques: Injection, Concentration Assay, Recombinant, Control